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The dorsal striatum is a major input structure of the basal ganglia and plays a key role in the control of vital processes such as motor
behavior, cognition, and motivation. The functionality of striatal neurons is tightly controlled by various metabotropic receptors.
Whereas the Gs/Gi-protein-dependent tuning of striatal neurons is fairly well known, the precise impact and underlying mechanism of
Gq-protein-dependent signals remain poorly understood. Here, using different experimental approaches, especially designer receptor
exclusively activated by designer drug (DREADD) chemogenetic technology, we found that sustained activation of Gq-protein signaling
impairs the functionality of striatal neurons and we unveil the precise molecular mechanism underlying this process: a phospholipase
C/Ca2!/proline-rich tyrosine kinase 2/cJun N-terminal kinase pathway. Moreover, engagement of this intracellular signaling route was
functionally active in themousedorsal striatum in vivo, as provenby thedisruptionofneuronal integrity andbehavioral tasks. Toanalyze
this effect anatomically,wemanipulatedGq-protein-dependent signaling selectively inneuronsbelonging to thedirect or indirect striatal
pathway. Acute Gq-protein activation in direct-pathway or indirect-pathway neurons produced an enhancement or a decrease, respec-
tively, of activity-dependent parameters. In contrast, sustained Gq-protein activation impaired the functionality of direct-pathway and
indirect-pathway neurons and disrupted the behavioral performance and electroencephalography-related activity tasks controlled by
either anatomical framework. Collectively, these findings define themolecularmechanismand functional relevance ofGq-protein-driven
signals in striatal circuits under normal and overactivated states.
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Introduction
The basal ganglia are a series of interconnected subcortical nuclei
including the striatum (caudate and putamen in primates), the
globus pallidus (internal and external segments), the subthalamic
nucleus, and the substantia nigra (pars reticulata and pars com-
pacta). They are a key node for many behavioral and neurobio-
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Significance Statement
The dorsal striatum is a major input structure of the basal ganglia and plays a key role in the control of vital processes such as
motor behavior, cognition, andmotivation.Whereas the Gs/Gi-protein-dependent tuning of striatal neurons is fairly well known,
the precise impact and underlying mechanism of Gq-protein-dependent signals remain unclear. Here, we show that striatal
circuits can be “turned on” by acuteGq-protein signaling or “turned off” by sustainedGq-protein signaling. Specifically, sustained
Gq-protein signaling inactivates striatal neurons by an intracellular pathway that relies on cJun N-terminal kinase. Overall, this
study sheds new light onto the molecular mechanism and functional relevance of Gq-protein-driven signals in striatal circuits
under normal and overactivated states.
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logical processes such as motor activity, cognitive functions, and
affective control. The vast majority ("95%) of neurons within
the striatum are GABAergic medium spiny neurons (MSNs),
which receive glutamatergic inputs primarily from the cortex and
from specific thalamic nuclei (Kreitzer, 2009). MSNs differ in
their neurochemical composition and form two major efferent
pathways. The direct pathway consists of MSNs expressing the
dopamine D1 receptor (D1R), substance P, and dynorphin. It
mainly projects to the substantia nigra pars reticulata and the
internal segment of the globus pallidus. The indirect pathway is
composed of MSNs expressing the dopamine D2 receptor (D2R),
adenosine A2A receptor, and enkephalin. It mainly projects to the
external segment of the globus pallidus, which, in turn, projects
to the subthalamic nucleus. Many conceptual models hypothe-
size that these two MSN populations oppose one another both
mechanistically and functionally (Nelson and Kreitzer, 2014).
However, obtaining empirical evidence to support their roles has
proven difficult because these cell populations are physically in-
termingled and morphologically indistinguishable. The imple-
mentation of optogenetics to control neuronal activity with
exquisite temporal resolution using engineered opsins has pro-
vided an expanding platform for decoding striatal functions
(Kreitzer and Berke, 2011; Freeze et al., 2013). More recently,
the designer receptor exclusively activated by designer drug
(DREADD) technology has been developed as a powerful tool for
controlling neuronal activity remotely (Jennings and Stuber,
2014; Lee et al., 2014). This chemogenetic method is based on the
expression of engineered G-protein-coupled receptors (GPCRs)
that are selectively and potently activated by systemically bio-
available, brain-penetrant and otherwise pharmacologically inert
ligands such as clozapine-N-oxide (CNO) (Armbruster et al.,
2007; Alexander et al., 2009). DREADDs have no detectable
constitutive activity and, by using conserved and canonical
GPCR-dependent signaling pathways, allow a spatiotemporally
selective and physiological manipulation of metabotropic signal-
ing pathways.
Metabotropic signaling is absolutely necessary for the proper
functioning of the striatum. Neurotransmitters/neuromodula-
tors such as dopamine, glutamate, adenosine, acetylcholine, and
endocannabinoids control the activity and plasticity of MSNs by
engaging various GPCR families. Specifically, the main dopa-
mine receptors present in MSNs, namely D1R and D2R, are cou-
pled to Golf and Gi proteins, respectively, and the detailed roles of
these signaling axes on striatal functions have been reported (Fer-
guson et al., 2011; Bock et al., 2013; Farrell et al., 2013; Ferguson
et al., 2013). Gq-coupled receptors such as metabotropic gluta-
mate mGlu1/5 receptors and muscarinic acetylcholine M1/3/5 re-
ceptors are also very important in the control ofMSN excitability
and an overactive Gq-protein-driven signaling has been shown to
occur in various models of basal ganglia-related diseases such as
Huntington’s disease and drug addiction (Conn et al., 2005; Kre-
itzer, 2009; Ribeiro et al., 2011; Girault, 2012; Cahill et al., 2014).
However, the precise impact and mode of action of Gq-protein
signaling onMSNs have not been clarified so far. Therefore, here,
we used different approaches, especially the DREADD chemoge-
netic technology, to examine the molecular mechanisms and
physiopathological relevance of Gq-protein signaling in direct-
pathway and indirect-pathway MSNs. Our findings unveil an
unprecedented molecular mechanism of Gq-protein-evoked
neuronal inactivation that is relevant in the disruption of striatal
functions in vivo.
Materials andMethods
Animals
We used mutant mice and their corresponding wild-type littermates in
which Cre recombinase expression was driven by the D1R promoter
(Monory et al., 2007; colony founders provided by Gu¨nther Schu¨tz, Ger-
man Cancer Research Center), the D2R promoter (colony founders pro-
vided by University of California Davis Knockout Mouse Project
Repository, Davis, CA), or both the D1R and D2R promoters (generated
by crossing the aforementioned D1R-Cre and D2R-Cre mouse lines). All
lines were in the C57BL/6N background. Wild-type C57BL/6N mice
were purchased from Harlan Laboratories. Animal housing, handling,
and assignment to the different experimental groups were conducted as
described previously (Bla´zquez et al., 2011). All experimental procedures
used were performed in accordance with the guidelines and with the
approval of the Animal Welfare Committee of Madrid Complutense
University according to the European Commission directives.
Viral vectors
Gq-coupled human M3 muscarinic DREADD (hM3Dq) fused to
mCherry (provided by Brian L. Roth, University of North Carolina,
ChapelHill, NC; Alexander et al., 2009) ormCherry alonewas subcloned
in a recombinant adeno-associated virus (rAAV) expression vector with
aminimal CAG promoter (for generalized expression) or in a CAG-DIO
vector (for Cre-dependent expression) using standardmolecular biology
techniques. For cell-specific ablation, a mCherry-FLEX-DTA cassette
(Addgene plasmid #58536, provided by Naoshige Uchida, Harvard Uni-
versity) was cloned in a CAG-DIO-rAAV vector. All vectors used were of
an AAV1/AAV2 mixed serotype and were generated by calcium phos-
phate transfection of HEK-293T cells and subsequent purification as
described previously (Monory et al., 2006).
DREADD-induced neuronal manipulation in vivo
Eight-week-old male C57BL/6N mice were injected stereotaxically with
CAG-hM3Dq-mCherry-rAAV or control CAG-rAAV (in 1.5 !l of PBS)
aimed at targeting the dorsal striatum. Each animal received 1 bilateral
Table 1. Cell signaling inhibitors used in combination with CNO for cell viability andWestern blot analyses
Product Target Final concentration Vehicle Supplier
U73122 PLC 5!M DMEM 0.5% DMSO Santa Cruz Biotechnology
U73343 PLC (inactive) 5!M DMEM 0.5% DMSO Santa Cruz Biotechnology
BAPTA-AM Intracellular Ca 2! 2!M DMEM 0.5% DMSO Santa Cruz Biotechnology
2-APB IP3 receptor 100!M DMEM 0.5% DMSO Santa Cruz Biotechnology
Bisindolylmaleimide PKC 2!M DMEM 0.5% DMSO Sigma-Aldrich
SP600125 JNK 12.5!M DMEM 0.5% DMSO Santa Cruz Biotechnology
U0126 MEK 25!M DMEM 0.5% DMSO Merck Millipore
LY294002 PI3K 10!M DMEM 0.5% DMSO Cell Signaling Technology
Akti-1/2 Akt 100 nM DMEM 0.5% DMSO Calbiochem
Rapamycin mTORC1 500 nM DMEM 0.5% DMSO Tecoland
ZVAD-FMK Pan caspases 5!M DMEM 0.5% DMSO Santa Cruz Biotechnology
Pepstatin A/E64D Ca 2!proteases 15/20!M DMEM Sigma-Aldrich
PF431396 FAK/PYK2 5!M DMEM 0.5% DMSO Tocris Bioscience
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injection at the following coordinates (to bregma): anteroposterior!0.5,
lateral#2.0, and dorsoventral$3.0. Four weeks after surgery, mice were
assigned to different experimental groups before starting the pharmaco-
logical treatments. Rotarod performance was analyzed along the last 3 d
of treatment.Micewere subsequently killed by intracardial perfusion and
their brains were excised for immunofluorescence analyses.
Eight-week-old wild-type, D1R-Cre, D2R-Cre, and/or D1R/D2R-Cre
micewere injected either unilaterally into the right brain hemisphere (for
assessing rotational behavior) or bilaterally (for assessing motor activity,
motor coordination, and sleep–wake pattern) with the Cre-dependent
CAG-DIO-hM3Dq-mCherry-rAAV at the aforementioned coordinates.
Animals were left untreated for 4 weeks after surgery before the pharma-
cological treatments and behavioral tests (see below).
Drug administration in vivo
CNO (Santa Cruz Biotechnology) was prepared fresh in saline (0.9%
NaCl) just before the experiments and injected intraperitoneally at 1 or
10 mg/kg. SP600125 (2H-dibenzo[cd,g]indazol-6-one) was dissolved in
45% (w/v) "-cyclodextrin (Sigma-Aldrich) and injected intraperitone-
ally at 15 mg/kg.
Behavioral and electroencephalographic assays
Spontaneous locomotor activity. D1R-Cre, D2R-Cre, and D1R/D2R-Cre
mice and their wild-type littermates were injected bilaterally with CAG-
DIO-hM3Dq-mCherry-rAAV as described above. After vector adminis-
tration, passive retro-reflective markers (B&L Engineering; diameter 7.9
mm,weight% 0.5 g) were attachedwith acrylic dental cement to the skull
Table 2. Statistical test used for each set of data
Figure Conditions n Analysis ( post hoc) Factor analyzed F-value p-value
2A Vehicle vs CNO/WT vs mutants 6–10 Two-way ANOVA (Bonferroni) Genotype F(1,55)& 6.23 %0.05
2A Vehicle vs CNO/WT vs mutants 6–10 Two-way ANOVA (Bonferroni) CNO treatment F(3,55)& 10.28 %0.01
2A Vehicle vs CNO/WT vs mutants 6–10 Two-way ANOVA (Bonferroni) Genotype' CNO treatment F(3,56)& 8.15 %0.01
2B Vehicle vs CNO/WT vs mutants 6–10 Two-way ANOVA (Bonferroni) Genotype F(3,57)& 1.36 (0.05
2B Vehicle vs CNO/WT vs mutants 6–10 Two-way ANOVA (Bonferroni) CNO treatment F(1,57)& 8.37 %0.01
2B Vehicle vs CNO/WT vs mutants 6–10 Two-way ANOVA (Bonferroni) Genotype' CNO treatment F(3,57)& 1.81 (0.05
2D Acute vs chronic 4–5 One-way ANOVA (Tukey) CNO treatment F(7)& 11.05 %0.01
2E Wake acute vs chronic 8–10 One-way ANOVA (Tukey) CNO treatment F(7)& 2.20 %0.05
2E Slow wave sleep acute vs chronic 7–10 One-way ANOVA (Tukey) CNO treatment F(7)& 4.32 %0.01
2E REM sleep acute vs chronic 7–9 One-way ANOVA (Tukey) CNO treatment F(7)& 2.12 0.05
3B Vehicle vs CNO/WT vs mutants 6–10 Two-way ANOVA (Bonferroni) Genotype F(3,56)& 1.40 (0.05
3B Vehicle vs CNO/WT vs mutants 6–10 Two-way ANOVA (Bonferroni) CNO treatment F(1,56)& 7.25 (0.05
3B Vehicle vs CNO/WT vs mutants 6–10 Two-way ANOVA (Bonferroni) Genotype' CNO treatment F(3,56)& 2.74 0.05
3C Vehicle vs CNO/WT vs mutants 6–10 Two-way ANOVA (Bonferroni) Genotype F(3,55)& 3.33 (0.05
3C Vehicle vs CNO/WT vs mutants 6–10 Two-way ANOVA (Bonferroni) CNO treatment F(1,55)& 8.16 %0.01
3C Vehicle vs CNO/WT vs mutants 6–10 Two-way ANOVA (Bonferroni) Genotype' CNO treatment F(3,55)& 4.81 (0.05
3D Vehicle vs CNO/WT vs mutants 5–10 Two-way ANOVA (Bonferroni) Genotype F(3,50)& 0.85 %0.05
3D Vehicle vs CNO/WT vs mutants 5–10 Two-way ANOVA (Bonferroni) CNO treatment F(1,50)& 7.75 %0.01
3D Vehicle vs CNO/WT vs mutants 5–10 Two-way ANOVA (Bonferroni) Genotype' CNO treatment F(3,50)& 1.26 %0.05
3G WT vs mutants 6–9 One-way ANOVA (Neuman–Keuls) Genotype F(3)& 8.25 %0.01
3H WT vs mutants/pre- vs post-rAAV 6–9 Two-way ANOVA (Bonferroni) Genotype F(3,39)& 2.87 %0.05
3H WT vs mutants/pre- vs post-rAAV 6–9 Two-way ANOVA (Bonferroni) AAV F(1,39)& 25 %0.01
3H WT vs mutants/pre- vs post-rAAV 6–9 Two-way ANOVA (Bonferroni) Genotype' AAV F(3,39)& 2.87 %0.05
3I WT vs mutants 5–9 One-way ANOVA (Neuman–Keuls) Genotype F(3)& 9.00 %0.01
4A Control vs hM3Dq-mCherry/CNO doses 8 Two-way ANOVA (Bonferroni) Nucleofection F(5,84)& 8.0 %0.01
4A Control vs hM3Dq-mCherry/CNO doses 8 Two-way ANOVA (Bonferroni) CNO treatment F(5,84)& 76 %0.01
4A Control vs hM3Dq-mCherry/CNO doses 8 Two-way ANOVA (Bonferroni) Nucleofection' CNO treatment F(5,84)& 6.11 %0.01
4B Intracellular signaling inhibitors 4–12 One-way ANOVA (Dunnet) Inhibitors F(13)& 11.66 %0.01
4C Mock vs shRNA/vehicle vs CNO 16 Two-way ANOVA (Bonferroni) Nucleofection F(5,180)& 6.46 %0.01
4C Mock vs shRNA/vehicle vs CNO 16 Two-way ANOVA (Bonferroni) CNO treatment F(1,180)& 92.15 %0.01
4C Mock vs shRNA/vehicle vs CNO 16 Two-way ANOVA (Bonferroni) Nucleofection' CNO treatment F(5,180)& 8.64 %0.01
4D Protein/time of treatment 3–4 Two-way ANOVA (Bonferroni) Protein F(3,55)& 2.18 (0.05
4D Protein/time of treatment 3–4 Two-way ANOVA (Bonferroni) Time of treatment F(5,55)& 13.67 %0.01
4D Protein/time of treatment 3–4 Two-way ANOVA (Bonferroni) Protein' time of treatment F(15,55)& 4.30 %0.01
4E Protein/inhibitor 3 Two-way ANOVA (Bonferroni) Protein F(3,32)& 0.92 (0.05
4E Protein/inhibitor 3 Two-way ANOVA (Bonferroni) Inhibitors F(4,32)& 16.47 %0.01
4E Protein/inhibitor 3 Two-way ANOVA (Bonferroni) Protein' inhibitors F(12,32)& 2.08 %0.05
5A Control vs hM3Dq-mCherry/CNO doses 8 Two-way ANOVA (Bonferroni) Infection F(5,84)& 7.07 %0.01
5A Control vs hM3Dq-mCherry/CNO doses 8 Two-way ANOVA (Bonferroni) CNO treatment F(5,84)& 33.94 %0.01
5A Control vs hM3Dq-mCherry/CNO doses 8 Two-way ANOVA (Bonferroni) Infection' CNO treatment F(5,84)& 4.89 %0.01
5B Vehicle vs CNO/vehicle vs inhibitors 8 Two-way ANOVA (Bonferroni) Inhibitors F(5,84)& 0.65 (0.05
5B Vehicle vs CNO/vehicle vs inhibitors 8 Two-way ANOVA (Bonferroni) CNO treatment F(1,84)& 3.98 %0.05
5B Vehicle vs CNO/vehicle vs inhibitors 8 Two-way ANOVA (Bonferroni) Inhibitors' CNO treatment F(5,84)& 1.11 (0.05
6A Vehicle vs CNO 4–5 Unpaired Student’s t test CNO treatment F(4)& 7.15 %0.05
6A CNO vs SP-CNO 4–5 Unpaired Student’s t test SP treatment F(4)& 6.03 %0.01
6C Vehicle vs CNO/CNO vs SP-CNO 5–8 One-way ANOVA (Tukey) Treatments F(5)& 8.14 %0.01
6D Vehicle vs CNO/CNO vs SP-CNO 10–11 One-way ANOVA (Tukey) Treatments F(5)& 3.00 %0.05
7A Vehicle vs CNO/CNO vs SP-CNO 5–8 One-way ANOVA (Tukey) Treatments F(5)& 6.42 %0.01
7B Vehicle vs CNO/CNO vs SP-CNO 5–8 One-way ANOVA (Tukey) Treatments F(5)& 2.82 %0.05
7C Vehicle vs CNO/CNO vs SP-CNO 5–8 One-way ANOVA (Tukey) Treatments F(5)& 3.51 %0.05
8B D1R vehicle vs CNO 7 One-way ANOVA (Tukey) Treatments F(2)& 7.27 %0.01
8B D2R vehicle vs CNO 6–7 One-way ANOVA (Tukey) Treatments F(2)& 11.02 %0.01
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of each mouse, which was single-housed in its cage. Acquisition (5 Hz
frequency) was performed using 3 OptiTrack Flex3 cameras (Natural
Point), allowing the continuous recording of the position of each animal
during dark and light phases. Acquisition and automated tracking soft-
ware were from MouvTech. Throughout the study, animals had unre-
stricted access to water and food and were subjected to a 12 h light/12 h
dark cycle. Offline analysis was performed using homemade software
developed with Matlab (The MathWorks). Mice were habituated to the
home cage for 7 d. Theywere then injectedwith vehicle (saline), followed
24 h later by acute CNO (1 mg/kg) and then by chronic CNO (10 mg/
kg/d for 14 d). Total locomotor activity in 12 h light/12 h dark cycles was
recorded.
Exploration, motor coordination, and spatial recognition. D1R-Cre,
D2R-Cre, and D1R/D2R-Cre mice and their wild-type littermates were
injected bilaterally with CAG-DIO-hM3Dq-mCherry-rAAV as de-
scribed above. They underwent a treatment schedule of 1 d of acute CNO
(1 mg/kg) followed by chronic CNO (10 mg/kg/d for 14 d) (or saline
vehicle). Exploration analyseswere conducted in an automated actimeter
(ActiTrack; Panlab; Bla´zquez et al., 2011) the first day of acute treatment
(1 h after injection), as well as after the last day of treatment. Motor
coordination (Rotarod test) and spatial recognition (Y-maze test) were
evaluated along the last 3 d of treatment before CNO administration to
avoid acute drug effects (Bla´zquez et al., 2011; Pietropaolo et al., 2015).
Sleep–wake pattern. D1R-Cre, D2R-Cre, and D1R/D2R-Cre mice and
their wild-type littermates were injected bilaterally with CAG-DIO-
hM3Dq-mCherry-rAAV as described above and implanted a multisite
electrode array for electroencephalographic recordings as described pre-
viously (Lebreton et al., 2015). Mice underwent two sessions of acute-
activation recording, one with vehicle (saline) and another, after 24 h,
with CNO (1 mg/kg) plus one session of chronic activation recording
after the last day of chronic CNO treatment (10mg/kg/d for 14 d or saline
vehicle). Electrophysiological data were analyzed as described previously
(Lebreton et al., 2015).
Rotational behavior.D1R-Cre and D2R-Cre mice were injected unilat-
erally with CAG-DIO-hM3Dq-mCherry-rAAV as described above.Mice
were then acutely injected with vehicle (saline) or, after 24 h, with CNO
(1 mg/kg); in both cases, animals were tested 1 h later in an open field.
Subsequently, animals were injected for 15 d with CNO (10 mg/kg/d)
together with SP600125 (15 mg/kg/d) or their respective vehicles. One
day after the last treatment, all mice were injected with vehicle and, after
24 h, with CNO (1 mg/kg); in both cases, animals were tested 1 h later in
an open field. Ipsilateral movements (complete turning to the right) and
contralateral movements (complete turning to the left) were assessed by
monitoring manually the total time spent in rotation for 5 min. No
rotations were observed in wild-type mice expressing CAG-DIO-
hM3Dq-rAAV and injected with vehicle or CNO.
Immunomicroscopy
Coronal free-floating sections (50 !m-thick) were obtained from
paraformaldehyde-perfusedmouse brains. Samples were incubated with
antibodies against dopamine- and cAMP-regulated phosphoprotein of
32 kDa (DARPP-32; 1:1000; BD Biosciences, #611520), NeuN (1:500;
Millipore, #MAB377), D1R (1:500; Frontier Science, #af500), D2R (1:
500; Frontier Science, #af750), choline acetyltransferase (ChaT; 1:1000;
Figure 1. Expression and activity of hM3Dq-mCherry in D1R-MSNs andD2R-MSNs in vivo. D1R-Cre andD2R-Cremicewere injected stereotaxically into the dorsal striatumwith CAG-DIO-mCherry-
rAAV (A) or CAG-DIO-hM3Dq-mCherry-rAAV (B, C), and left untreated for 4 weeks. A, Representative images delineating the connectivity from the striatum to output nuclei in D1R-Cre and D2R-Cre
mice. Str, Striatum; GPe, external globus pallidus; GPi, internal globus pallidus; SNr, substantia nigra pars reticulata. Scale bar, 1 mm. B, Fluorescence colabeling of D1R/mCherry and D2R/mCherry
shows the specificity of Cre-driven recombination. Examples of cells that are double-positive for D1R/mCherry or D2R/mCherry are indicated by arrows. Scale bar, 30!m. C, Animals subsequently
received one single intraperitoneal injection of vehicle or CNO (1 mg/kg) and, after 2 h, were killed for cFos immunohistochemistry. Scale bar, 75!m.
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Merck, #AB144P) or cFos (1:2000; Santa Cruz Biotechnology, #SC52),
followed by staining with the corresponding Alexa Fluor 488, 594, or 647
antibodies (1:1000; Life Technologies) or with HRP-coupled secondary
antibodies plus DAB chromogenic visualization (Vector Laboratories)
(Bla´zquez et al., 2011). Nuclei were visualized with DAPI. Analysis of
marker protein immunoreactivity in the dorsal striatum was conducted
in a 1-in-10 series per animal (from bregma!1.5 to$0.5 coronal coor-
dinates). For DARPP-32, D1R, and D2R, data were calculated as immu-
Figure2. SustainedGq-protein signaling disrupts the balanced control of behavior exerted by D1R-MSNs andD2R-MSNs in vivo.Wild-type, D1R-Cre, D2R-Cre, andD1R/D2R-Cremicewere injected
stereotaxically into the dorsal striatumwith CAG-DIO-hM3Dq-mCherry-rAAV and left untreated for 4 weeks. A, Animals subsequently received one single intraperitoneal injection of vehicle or CNO
(1mg/kg) and, 1 h later, their ambulationwas tested in an open field.B, Animals subsequently received one daily intraperitoneal injection of vehicle or CNO (10mg/kg) for 14 consecutive days and
their ambulation was tested in an open field. C, D, Animals used for continuous ambulatory activity recordings were implanted during surgery light-reflecting devices. They subsequently received
one single intraperitoneal injection of vehicle, followedafter 24hby CNO (1mg/kg; acute CNO) and, after 24h, onedaily intraperitoneal injection of vehicle or CNO (10mg/kg) for 14 consecutive days
(chronic CNO). Total daily ambulations for the 12 h light period (7:00–19:00), expressed as percentage of vehicle treatment, are shown for 16 consecutive days (C), as well as for the acute day and
the last chronic-treatment day (D). E, Animals used for electroencephalographic recordingswere implanted during surgerywith electrode-miniature array devices. They subsequently underwent 2
sessions of acute-activation electroencephalographic recording, onewith vehicle (saline) and another, after 24 h,with CNO (1mg/kg) plus one session of chronic-activation electroencephalographic
recording after the last day of chronic CNO treatment (10 mg/kg/d for 14 consecutive days; or saline vehicle). In each case, animals were subjected to recording for 3 h and sleep–wake changes
induced by CNO treatmentwere expressed as percentage of the respective vehicle treatment. *p% 0.05, **p% 0.01 from the corresponding vehicle group (A,B) or thewild-type group (D, E). See
details of statistical analyses in Table 2.
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Figure 3. Diphtheria-toxin-mediated ablation of D1R-MSNs and D2R-MSNs recapitulates the behavioral phenotype of sustained Gq-protein signaling. A–D, Wild-type, D1R-Cre, D2R-Cre, and
D1R/D2R-Cremicewere injected stereotaxically into thedorsal striatumwithCAG-DIO-hM3Dq-mCherry-rAAVand left untreated for 4weeks. Animals subsequently receivedonedaily intraperitoneal
injection of vehicle (saline) or CNO (10mg/kg) for 2 consecutiveweeks. Shown is the scheme of the chronic CNO treatment experiment. The arrows indicate injections (blue, rAAV; red, vehicle/CNO;
A). Effect of chronic CNO treatmentonambulation (open field;B),motor coordination (Rotarod;C), and spatial recognition (Y-maze;D).E–I,Wild-type,D1R-Cre,D2R-Cre, andD1R/D2R-Cremicewere
injected stereotaxically into the dorsal striatum with a rAAV encoding mCherry-FLEX-DTA and left untreated for 4 weeks. Scheme of the diphtheria toxin (Figure legend continues.)
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noreactive area per total cell nuclei and are expressed as a percentage of
the control. D1R and D2R immunofluorescence was counted simultane-
ously, so these are shown in the same samples. For NeuN and ChaT, data
were calculated as number of positive cells per total cell nuclei and ex-
pressed as percentage of the control. Confocal fluorescence images
were acquired using TCS-SP2 software and a SP2 AOBS microscope
(Leica). Pixel quantification and colocalization were analyzed with
ImageJ software.
Western blotting
Western blot analysis was conductedwith antibodies raised against phos-
phorylated ERK (1:1000; Cell Signaling Technology, #9101), total ERK
(1:1000; Cell Signaling Technology, #9102), phosphorylated JNK (1:
1000; Cell Signaling Technology, #9255), total JNK (1:1000; Cell Signal-
ing Technology, #9252), phosphorylated cJun (1:1000; Cell Signaling
Technology, #2361), total cJun (1:1000; Cell Signaling Technology,
#9156), phosphorylated PYK2 (1:1000; Cell Signaling Technology,
#3291), total PYK2 (1:1000; Cell Signaling Technology, #3480), and
"-tubulin III (1:4000; Sigma-Aldrich, #T8660), following standard pro-
cedures (Bla´zquez et al., 2015). Densitometric analysis was performed
with Quantity One software (Bio-Rad).
Cell culture
Conditionally immortalized mouse striatal neuroblasts infected with a
defective retrovirus transducing the temperature-sensitive A58/U19
large T antigen (Trettel et al., 2000; designated as STHdh cells; provided
by Silvia Gine´s, University of Barcelona, Spain) were grown at 33°C in
DMEM supplemented with 10% fetal bovine serum, 1mM sodium pyru-
vate, 2 mM L-glutamine, and 400 !g/ml geneticin (Bla´zquez et al., 2011).
Cells were devoid of mycoplasma contamination.
Primary striatal neurons were obtained from 2-d-old C57BL/6Nmice
using a papain dissociation system (Worthington). Striata were dissected
and cells were seeded on plates precoatedwith 0.1mg/ml poly-D-lysine at
200,000 cells/cm2 in Neurobasal medium supplemented with B27 and
Glutamax (Bla´zquez et al., 2015).
Cell nucleofection and infection
STHdh cells were nucleofected with a construct expressing hM3Dq-
mCherry (or mCherry alone as control) under the CAG promoter (see
above) using an Amaxa mouse neuron nucleofector kit (Lonza). Two
days after nucleofection, cells were treated in 0.5% FBS medium with
CNO (or H2O as vehicle) in the presence of different signaling pathway
inhibitors (Table 1). Cells were treated for up to 8 h for cell viability or
Western blot assays (Bla´zquez et al., 2015). In a second set of experi-
ments, the CAG-hM3Dq-mCherry construct was conucleofected with
plasmids expressing shRNA directed to Jnk1, Jnk2, Jnk3, or Pyk2 or a
scrambled control (Origene). The extent of silencing induced by the
different kinase-directed shRNA, as determined by RT-PCR, ranged be-
tween 50% and 80% relative to the scrambled control. In a third set of
experiments, STHdh cells were nucleofectedwith aCAG-DTA construct.
Primary neurons were infected at day 2 in vitro with a rAAV expressing
hM3Dq (or GFP as control) and kept until day 13 in vitro for cell viability
experiments.
Statistics
Data are presented as mean # SEM. Statistical comparisons were made
by one-way or two-way ANOVA with post hoc Bonferroni, Tukey, or
Neuman–Keuls test or by unpaired Student’s t test. The precise statistical
analysis made for each figure panel is shown in Table 2. p % 0.05 was
considered significant.
Results
Sustained Gq-protein signaling disrupts the balanced control
of behavior exerted by D1R-MSNs and D2R-MSNs in vivo
To study the impact ofGq-driven signaling on striatal circuits, we set
up an experimental model to manipulate direct-pathway or
indirect-pathwayMSNs selectively and reliably in vivo. For this pur-
pose,we first injected aFLEX(CAG-DIO) rAAVencodingmCherry
into the dorsal striatum of D1R-Cre and D2R-Cre mice, which al-
lowed delineating the connectivity to output nuclei (Fig. 1A).
Counting of mCherry-positive cells in D1R-Cre and D2R-Cre mice
showed that recombinationwas slightly higher in the formermouse
line (63# 5% and 40# 4% of mCherry-positive cells in D1R-Cre
and D2R-Cre mice, respectively; n& 7 animals per group).We also
analyzed mCherry expression in ChaT-positive interneurons and
found that our CAG-DIO-rAAV-driven infection procedure gener-
ated no detectable recombination in D1R-Cre mice (0% of ChaT-
positive cells infected; n & 7 mice) and only a negligible
recombination in D2R-Cre mice (%3% of ChaT-positive cells in-
fected; n & 7 mice). Next, a CAG-DIO-rAAV encoding hM3Dq
fused tomCherrywas injected in the same experimental conditions.
The Cre-driven expression of the transgene was achieved selectively
in D1R-MSNs and D2R-MSNs, as evidenced by D1R/mCherry and
D2R/mCherry colabeling analyses (Fig. 1B).Moreover, the ability of
the transgene to trigger neuronal activation was proven by the en-
hanced cFos immunoreactivity observed in the striata of D1R-Cre
and D2R-Cre mice (but not wild-type mice) that had been acutely
treated with CNO (one single intraperitoneal injection at 1 mg/kg;
Alexander et al., 2009; Fig. 1C).
In a first experimental paradigm aimed at assessing dorsal
striatum functionality, we observed that acute activation of Gq-
protein signaling in D1R-MSNs enhanced exploratory activity in
an open field, whereas acute activation in D2R-MSNs produced
the opposite effect (Fig. 2A). Strikingly, upon chronic CNO treat-
ment (one daily intraperitoneal injection of CNO at 10mg/kg for
14 d; Alexander et al., 2009; Chiarlone et al., 2014) the acute
Gq-evoked hyperlocomotor reactivity on D1R-MSNs was abol-
ished and the acuteGq-evokedhypolocomotor reactivity onD2R-
MSNs did not only disappeared, but even turned to an opposite
hyperlocomotor reactivity (Fig. 2B).
In a second experimental paradigm, the effect of acute and
chronic Gq activation in the direct or indirect pathway was mon-
itored using passive retro-reflective markers attached to the head
of each mouse expressing hM3Dq-mCherry in D1R-MSNs or
D2R-MSNs. Singly housed mice were thus continuously tracked
in their home cage during 16 consecutive days under vehicle (one
single intraperitoneal saline injection), acute CNO (one single
intraperitoneal injection at 1mg/kg the day after) and subsequent
chronic CNO (one daily intraperitoneal injection at 10mg/kg for
14 d). Consistent with the aforementioned open-field data, acute
Gq activation in D1R-MSNs increased continuous ambulatory
activity, whereas acute Gq activation in D2R-MSNs led to the
opposite outcome (Fig. 2C,D). Sustained Gq activation in D1R-
MSNs abolished the acute hyperactivity, whereas sustained Gq
activation in D2R-MSNs turned the acute hypoactivity into hy-
peractivity (Fig. 2C,D). These behavioral changes were visible
only during light cycle (data not shown for dark cycle). The dif-
ferent response to chronic CNO treatment shown by D1R/D2R-
Cre mice in Figure 2, C and D, versus Figure 2B most likely
reflects the different type of test used, namely locomotor activity
in the home cage versus locomotor reactivity in a novel environ-
ment. The latter can be subjected to other behavioral compo-
4
(Figure legend continued.) expression experiment. The blue arrow indicates rAAV injections
(E). Fluorescence labeling ofmCherry and DARPP-32 shows the effect of Cre-driven recombina-
tion in the mCherry-FLEX-DTA animals. Scale bar, 50!m (F). Effect of diphtheria toxin expres-
sion on ambulation (open field; G), motor coordination (Rotarod; H), and spatial recognition
(Y-maze; I). *p% 0.05, **p% 0.01 from the corresponding vehicle group (B–D), wild-type
group (G, I), or pre-rAAV group (H). See details of statistical analyses in Table 2. DTA, Diphtheria
toxin fragment A.
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Figure 4. Sustained Gq-protein signaling induces the death of STHdh cells via PLC/Ca
2!/PYK2/JNK. STHdh cells were nucleofected with constructs expressing hM3Dq-mCherry or mCherry.
A, Cellswere incubated for 8 hwith vehicle or the indicateddoses of CNO.B, Cellswere incubated for 8 hwith vehicle or 50!MCNO, togetherwith vehicle or the indicated additions (see experimental
details in Table 1). C, Cellswere also nucleofectedwith a nontargeted shRNA, orwith shRNAs directed against Jnk1, Jnk2, Jnk3, or Pyk2 and subsequently incubated for 8 hwith vehicle or 50!MCNO.
Relative cell viability is shown in all panels.D, STHdh cellswere incubated for the times indicatedwith vehicle or 50!MCNO.E, STHdh cellswere incubated for 2 hwith vehicle or 50!MCNO, together
with vehicle or the indicated additions (see experimental details in Table 1). InD and E, the representativeWestern blots with themolecular weight of the protein bands (left) and quantification of
optical density values of the protein bands relative to those of loading controls (right) are shown. In E (left), images from different parts of the same gel or from different gels were grouped. *p%
0.05, **p% 0.01 from the corresponding vehicle-treated cells. #p% 0.05, ##p% 0.01 from the corresponding CNO-vehicle-treated cells. See details of statistical analyses in Table 2. Bis,
Bisindolylmaleimide; Pep, pepstatin A.
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nents such as anxiety and risk assessment, which, however, fall
beyond the scope of the present study.
A third experimental paradigm was used to evaluate whether
the aforementioned behavioral changes in activity were accom-
panied by actual electroencephalographic changes, specifically in
the sleep–wake pattern. Therefore, we found that acute Gq acti-
vation in D1R-MSNs, in concert with hyperactivity, produced an
increased amount of wake (Fig. 2E, left), as well as a decreased
time spent in both slow-wave (Fig. 2E, middle) and rapid eye
movement (REM) sleep (Fig. 2E, right). Acute Gq activation in
D2R-MSNs, in concert with hypoactivity, induced an increased
amount of sleep, specifically in the slow-wave phase (Fig. 2E,
middle). Conversely, sustained Gq activation in D1R-MSNs abol-
ished, not only the acute hyperactivity, but also the acute wake-
fulness state (Fig. 2E, left), whereas sustained Gq activation in
D2R-MSNs not only induced hyperactivity, but also enhanced
the time spent inwake (Fig. 2E, left) and reduced the time spent in
REM sleep (Fig. 2E, right). Spectral analysis of electroencephalo-
grams did not reveal changes inmajor brain rhythms in the delta,
theta, or gamma frequencies during different vigilance states
(data not shown).
Collectively, these findings show that direct-pathway and
indirect-pathway MSNs can be “turned on” by acute Gq-protein
signaling or “turned off” by sustained Gq-protein signaling in vivo.
Diphtheria-toxin-mediated ablation of D1R-MSNs and
D2R-MSNs recapitulates the behavioral phenotype of
sustained Gq-protein signaling
To evaluate whether the observed changes elicited by sustained
Gq-protein signaling in vivo are due to the dysfunction of MSNs,
we first analyzed the immunoreactivity of the MSN marker
DARPP-32 in D1R-Cre and D2R-Cre mice expressing hM3Dq-
mCherry in the dorsal striatum. Chronic CNO treatment (10
mg/kg/d for 2 consecutive weeks) decreased DARPP-32 immu-
noreactivity similarly in D1R-Cre mice (relative value of CNO vs
vehicle: 62 # 6%; n & 8–9 animals per group; p % 0.01) and
D2R-Cre mice (relative value of CNO vs vehicle: 70 # 5%; n &
7–8 animals per group; p% 0.01). This regime of CNO adminis-
tration had no significant effect on wild-type mice injected with
CAG-DIO-hM3Dq-mCherry-rAAV (relative value of CNO vs
vehicle: 96# 9; n& 7–9 animals per group). Next, we evaluated
the behavioral phenotype of D1R-Cre andD2R-Cremice that had
been injected stereotaxically into the dorsal striatum with a
FLEX-rAAV encoding diphtheria toxin, which is well known to
produce cell-population-specific ablation (Kreitzer and Berke,
2011; Durieux et al., 2012; Kim et al., 2014). We selected three
behavioral tests that rely at least in part on the dorsal striatum: the
open field (to assess exploratory activity), Rotarod (to assess mo-
tor coordination), and Y-maze (to assess short-term spatial
memory), and compared the phenotype of chronic CNO-treated
hM3Dq-mCherry-expressing mice (Fig. 3A) with that of
diphtheria-toxin-expressing mice (Fig. 3E,F). Overall, the dis-
rupting effects evoked by the selective expression of diphtheria
toxin in D1R-MSNs or D2R-MSNs recapitulated very closely the
respective changes elicited by sustained Gq signaling in the two
MSNpopulations. Specifically, aside from the exploration assays,
in which either chemogenetically or diphtheria toxin-induced
dysfunction of D2R-MSNs enhanced locomotor activity (Fig.
3B,G), we found that either chemogenetically or diphtheria-
toxin-induced dysfunction of D1R-MSNs impaired motor
coordination (Fig. 3C,H), whereas either chemogenetically or
diphtheria-toxin-induced dysfunction of D2R-MSNs impaired
short-term spatialmemory (Fig. 3D, I; no differences in total arm
entries were found among the different animal groups tested;
data not shown). The lack of motor coordination deficits shown
by our D2R-Cre mice upon chronic CNO administration (Fig.
3C), compared with the data reported byDurieux et al. (2012) on
mice in which A2AR-expressing neurons had been ablated, could
be due to the different experimental conditions used. Therefore,
we only analyzed Rotarod performance after training, whereas
they found a Rotarod impairment only at the beginning of the
training period, after which animals reached the same values as
controls. Their D1R-MSN-ablated mice showed, like ours, a per-
sistent Rotarod impairment also at the end of the training period
(Durieux et al. (2012).
Together, these observations suggest that sustained Gq-protein
signaling might impair striatal circuits in vivo by inducing the inac-
tivation of direct-pathway and indirect-pathwayMSNs.
Figure 5. Sustained Gq-protein signaling induces the death of striatal neurons. A, Primary
mouse striatal neurons were infected with CAG-hM3Dq-mCherry-rAAV or control CAG-GFP-
rAAV at day 2 in vitro. At day 13 in vitro, they were incubated for 8 hwith the indicated doses of
CNO. Quinolinic acid (QA) was used as a control neurotoxin to demonstrate a comparable sen-
sitivity to death of CAG-hM3Dq-mCherry-rAAV-infected neurons and CAG-GFP-rAAV-infected
neurons. B, Primarymouse striatal neurons were infected with hM3Dq-mCherry-rAAV at day 2
in vitro. At day 13 in vitro, theywere incubated for 8 hwith vehicle or 50!M CNO, togetherwith
vehicle or the indicated additions (see experimental details in Table 1). *p% 0.05, **p% 0.01
from the corresponding vehicle-treated cells. See details of statistical analyses in Table 2.
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Sustained Gq-protein signaling induces
the death of MSNs via a
PLC/Ca2!/PYK2/JNK pathway
To analyze the molecular mechanism of
Gq-driven action on MSNs, we first used
cultures of STHdh mouse striatal neuro-
blasts, a well established MSN-like cell
model (Trettel et al., 2000). Cells were
electroporated with a plasmid encoding
hM3Dq-mCherry (or only mCherry) and
subsequently treated with CNO (or vehi-
cle). Exposure of cells expressing hM3Dq-
mCherry (but not mCherry) to CNO
decreased viability in a dose-dependent
manner (Fig. 4A). From these assays, a
dose of 50 !M CNO was selected for fur-
ther experiments aimed at deciphering
the signal transduction pathways re-
sponsible for Gq-driven cell death (Ta-
ble 1). The phospholipase C (PLC)
inhibitor U73122 (but not its inactive
analog U73343), the intracellular Ca2!
chelator BAPTA-AM, and the intracellu-
lar Ca2!-release inhibitor 2-APB pre-
vented Gq-evoked cell death (Fig. 4B),
thus supporting the involvement of PLC/
Ca2! signaling. In contrast, the general
protein kinase C (PKC) inhibitor bisin-
dolylmaleimide was ineffective. When
assessing potential downstream effectors
of PLC/Ca2!, we found that the cJun
N-terminal kinase (JNK) inhibitor SP600125
prevented Gq-induced cell death, whereas
blockade of the extracellular signal-
regulated kinase (ERK) cascade (with the
MEK inhibitor U0126), phosphatidylino-
sitol 3-kinase (PI3K; with LY294002), Akt
(with Akti-1/2), or mammalian target of
rapamycin complex 1 (mTORC1; with
rapamycin) did not affect Gq action (Fig.
4B). Gq-driven STHdh cell death was
caspase independent (as evidenced by the
lack of effect of the pan-caspase inhibitor
ZVAD-FMK), but lysosome dependent (as inferred from the pre-
ventive effect of the lysosomal-protease/cathepsin inhibitors
pepstatin A and E64d; Fig. 4B).
To further clarify the involvement of the JNK cascade in cell
death, we conducted additional experiments in STHdh cells.
First, Gq-evoked cell death was prevented by a shRNA targeting
JNK3, the most relevant of the three JNK family members in the
brain (Fig. 4C). Second, Western blot experiments showed that
activation of Gq signaling led to a sustained (up to 8 h) phosphor-
ylation (activation) of JNK, which was accompanied by a phos-
phorylation (activation) and stabilization (increased levels) of its
canonical substrate, the transcription factor cJun (Fig. 4D). In
contrast, the phosphorylation (activation) of ERK, which was
used as a control pathway triggered by acute Gq-evoked activa-
tion (Girault, 2012), was only transient and returned to basal
levels after 2 h of CNO challenge (Fig. 4D). Third, consistent with
the aforementioned cell death experiments, the sustained Gq-
evoked activation of JNK and cJun was PLC/Ca2! dependent (as
shown by the preventive effect of U73122 and BAPTA-AM) and
PKC independent (as shown by the lack of effect of bisindolylma-
leimide; Fig. 4E).
Wenext investigated the link betweenCa2! and JNK. Proline-
rich tyrosine kinase 2 (PYK2) is a cytoplasmic nonreceptor ty-
rosine kinase enriched in neurons that controls various
neurobiological functions and that, by acting as a Ca2! effector,
can activate mitogen-activated protein kinase cascades (Girault
et al., 1999). Therefore, we investigated whether PYK2 was in-
volved in our experimental setting. The Gq-evoked death of
STHdh cells was prevented by the dual PYK2/focal adhesion ki-
nase inhibitor PF431396 (Fig. 4B), as well as by a Pyk2-directed
shRNA (Fig. 4C). Likewise, activation of Gq signaling led to the
phosphorylation (activation) of PYK2 and this effect was pre-
vented by U73122 and BAPTA-AM, but not by SP600125 (Fig.
3E), thus supporting that PYK2 is downstream of PLC/Ca2! and
upstream of JNK.
We subsequently investigatedwhether theGq-triggered effects
observed in STHdh cells could be extrapolated to a more physi-
ological experimental model as primary striatal neurons. Indeed,
Figure 6. Sustained Gq-protein signaling disrupts the functionality of striatal neurons in vivo via JNK. C57BL/6N mice were
injected stereotaxically into the dorsal striatum with CAG-hM3Dq-mCherry-rAAV or control CAG-rAAV and left untreated for 4
weeks. A, Animals subsequently received a single intraperitoneal injection of vehicle or CNO (10 mg/kg), together with a single
intraperitoneal injection of vehicle or SP600125 (15 mg/kg), and, after 2 h, their dorsal striata were excised for Western blot
analysis. Quantificationof optical density values of phosphorylated cJun relative to thoseof the loading control (total cJun; top) and
representative Western blots (bottom) are shown. B–D, Animals subsequently received one daily intraperitoneal injection of
vehicle or CNO (10mg/kg), togetherwith one daily intraperitoneal injection of vehicle or SP600125 (15mg/kg), for 10 consecutive
days. Shown are representative images of NeuN immunostaining. Scale bar, 50 !m (B). Shown is the quantification of NeuN
expression (relative values of NeuN-positive cells; C) andRotarod test performance (latency to fall;D). *p% 0.05, **p% 0.01 from
the corresponding vehicle-vehicle group; #p % 0.05, ##p % 0.01 from the corresponding CNO-vehicle group. See details of
statistical analyses in Table 2.
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activation of Gq signaling upon challenge of hM3Dq-mCherry-
expressing primary mouse striatal neurons to CNO also led to a
PLC/Ca2!/JNK-dependent, ERK-independent cell death process
(Fig. 5A,B).
In sum, these data show that sustained Gq-protein activa-
tion signals neuronal cell death via a PLC/Ca2!/PYK2/JNK-
dependent pathway.
Sustained Gq-protein signaling disrupts the functionality of
D1R-MSNs and D2R-MSNs in vivo via JNK
To evaluate the functional relevance of JNK in vivo, we first in-
jected C57BL/6N mice stereotaxically into the dorsal striatum
with a rAAV encoding hM3Dq-mCherry (or control rAAV). The
transgene was driven by the CAG promoter to allow its expres-
sion in all MSNs. In agreement with our aforementioned cell
culture observations, engagement of Gq signaling (one single in-
traperitoneal injection of CNO at 10mg/kg in hM3Dq-mCherry-
expressing mice) triggered striatal JNK activation in vivo, as
determined by the SP600125-sensitive phosphorylation (activa-
tion) of cJun (Fig. 6A; we were unable to obtain technically reli-
able Western blots frommouse striatal extracts with commercial
anti-pJNK antibodies). Furthermore, af-
ter sustainedGq signaling (one daily intra-
peritoneal injection of CNO at 10 mg/kg
for 10 d), we found a loss of MSNs, as
determined by the reduction of the neu-
ronal marker NeuN (Fig. 6B,C) and the
MSN marker DARPP-32 (Fig. 7A). This
loss of MSNs was equally evident in the
D1R-MSN population (Fig. 7B) and the
D2R-MSN population (Fig. 7C). More-
over, these alterations in neuronal mark-
ers were accompanied by a deficit in the
Rotarod test (Fig. 6D), a well established
behavioral readout of the dorsal striatum.
Remarkably, these Gq-evoked effects were
prevented by pharmacological blockade
of JNK (Figs. 6B–D, 7A–C) and were not
simply caused by the viral expression of a
novel receptor or by an off-target action of
CNO (either hM3Dq-mCherry expres-
sion in the absence of CNO or treatment
of control rAAV-infected animals with
CNO was ineffective; Figs. 6A–D, 7A–C).
Finally, we assessed whether JNK-
driven signaling affects either the direct
pathway or the indirect pathway sepa-
rately by monitoring a clear-cut behav-
ioral task as contraversive movements
(Tecuapetla et al., 2014). Selective acute
unilateral activation of Gq signaling in
D1R-MSNs or D2R-MSNs induced con-
tralateral or ipsilateral movements, re-
spectively (Fig. 8A). This acute effect was
abrogated in those animals that had been
chronically treatedwithCNO (Fig. 8B). In
turn, this impairing effect of chronic
CNO treatment on contralateral/D1R-
MSN-dependent movements (Fig. 8B,
left) and ipsilateral/D2R-MSN-dependent
movements (Fig. 8B, right)was rescued by
the coadministration of a JNK inhibitor to
the animals.
Collectively, these data show that JNK mediates the inactiva-
tion of MSNs and the disruption of striatal circuits evoked by
sustained Gq-protein signaling in vivo.
Discussion
Here, we manipulated MSNs selectively by means of the
DREADD technology to unveil howGq-protein-evoked signaling
affects neuronal functionality. A DREADDi approach was used
previously to study the effects of the selective inhibition of D1R-
MSNs or D2R-MSNs in the rat dorsomedial striatum by express-
ing hM4Di in a herpes virus vector with promoter elements for
dynorphin or enkephalin, respectively (Ferguson et al., 2011).
CNO administration did not change acute locomotor responses
to amphetamine, but altered behavioral plasticity associated with
repeated drug treatment (Ferguson et al., 2011). A similar ap-
proach found that the hM4Di-evoked inhibition ofD2R-MSNs in
the mouse nucleus accumbens enhanced the motivation to ob-
tain cocaine (Bock et al., 2013). Collectively, these and other
related studies demonstrate that chemogenetic manipulation of
MSNs with DREADDs (Farrell et al., 2013; Ferguson et al., 2013),
DREADDi (Ferguson et al., 2011; Bock et al., 2013; Ferguson et
Figure 7. Sustained Gq-protein signaling induces the loss of MSNs in vivo via JNK. C57BL/6Nmice were injected stereotaxically
into the dorsal striatum with CAG-hM3Dq-mCherry-rAAV or control CAG-rAAV, and left untreated for 4 weeks. Animals subse-
quently received one daily intraperitoneal injection of vehicle or CNO (10mg/kg), togetherwith one daily intraperitoneal injection
of vehicle or SP600125 (15 mg/kg), for 10 consecutive days. A, DARPP-32 expression (relative values of DARPP-32 immunoreac-
tivity). B, D1R expression (relative values of D1R immunoreactivity). C, D2R expression (relative values of D2R immunoreactivity).
Representative images are shown in all panels. Scale bar, 50!m. *p% 0.05, **p% 0.01 from the corresponding vehicle/vehicle
group; #p% 0.05 from the corresponding CNO/vehicle group. See details of statistical analyses in Table 2.
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al., 2013) or DREADDq (the present study) is a viable tool to
assess the impact of specific G-protein-mediated signals on the
conceptually proposed opposing roles of the direct and indirect
striatal pathways. Moreover, the lack of effect of MSN inhibition
(via DREADDi) on acute locomotor responses (Ferguson et al.,
2011) compared with the remarkable effects of MSN activation
via DREADDs (Ferguson et al., 2013) or DREADDq (the present
study) points to a hierarchical subordination of inhibitory to
stimulatory metabotropic pathways in simple behavioral tasks.
Likewise, Gq, Gs, and Gi-coupled DREADD-mediatedmanipula-
tion of the circadian pacemaker in the mouse suprachiasmatic
nucleus showed a prominent role of the Gq axis over Gi (and Gs)
signaling in controlling circadian rhythms (Brancaccio et al.,
2013). In contrast, significant—and opposing—effects of Gq and
Gi signaling per se were found upon the chemogenetic manipu-
lation of, for example, mouse agouti-related protein-expressing
neurons (Krashes et al., 2011) and calcitonin-gene-related
peptide-expressing neurons (Carter et al., 2013) in the control of
feeding behavior. Therefore, it is conceivable that the actual rel-
ative strength of Gq, Gs, and Gi signals to control neural activity
varies significantly among different brain regions and biological
processes in vivo.
The precisemetabotropicmechanisms involved in the control
of the integrity and function ofMSNs are not fully understood. A
large body of evidence supports that cAMP-dependent cascades
are highly relevant and, in fact, both DREADDs and DREADDi
alter neuronal activity and plasticity in striatal circuits through
changes in cAMP production (Ferguson et al., 2011; Bock et al.,
2013; Farrell et al., 2013; Ferguson et al., 2013). Activation of
Golf-coupled D1R in direct-pathway MSNs engages multiple sig-
naling pathways, such as protein kinase A, ERK, and CREB, by
increasing cAMP production, whereas activation of Gi-coupled
D2R in indirect-pathway MSNs leads to downregulation of these
cascades (Girault, 2012; Cahill et al., 2014). Other Gs-coupled
receptors (e.g., adenosineA2A receptors, which aremostly located
in striatopallidalMSNs) andGi-coupled receptors (e.g., cannabi-
noid CB1 receptors, which are highly enriched in the terminals of
both striatonigral and striatopallidal MSNs) make a major con-
tribution as well to tuning the functioning of basal ganglia cir-
cuits via cAMP and other related intracellular signals (Kreitzer,
2009; Girault, 2012).
The class I metabotropic glutamate receptors mGlu1 and
mGlu5 are the most relevant group of striatal Gq-coupled recep-
tors. Although activation of the ERK pathway in the striatum can
be readily achieved by D1R and ionotropic (NMDA) glutamate
receptors, mGlu1/5 receptors also activate ERK through Ca
2! re-
lease from intracellular stores in synergy with D1R, thereby par-
ticipating, for example, in drug-induced behavioral plasticity
(Girault, 2012). However, here, by manipulating Gq-evoked ac-
tivity selectively inMSNs, we unveil that JNK, rather than ERK or
other signaling pathways such as PKC and PI3K/Akt/mTORC1,
is the key functional effector of the Gq/PLC/Ca
2! axis (Fig.
9A,B). Glutamate has been shown to stimulate JNK in striatal
neurons (Schwarzschild et al., 1997) and to cooperate with dopa-
Figure 8. Sustained Gq-protein signaling disrupts the functionality of D1R-MSNs and D2R-MSNs in vivo via JNK.Wild-type, D1R-Cre, and D2R-Cremice received a unilateral injection into the right
dorsal striatum of CAG-DIO-hM3Dq-mCherry-rAAV andwere left untreated for 4weeks. A, Animals subsequently received a single injection of vehicle or, after 24 h, of CNO (1mg/kg); in both cases,
animals were tested 1 h later in an open field. A scheme of this acute CNO treatment experiment is shown on top. The arrows indicate injections (blue, rAAV; red, vehicle/CNO). B, Animals
subsequently received one daily intraperitoneal injection of vehicle or CNO (10mg/kg), together with one daily intraperitoneal injection of vehicle or SP600125 (15mg/kg), for 15 consecutive days.
Oneday after the last treatment, allmicewere injectedwith vehicle and, after 24 h,with CNO (1mg/kg); in both cases, animalswere tested 1h later in an open field (left, D1R-Cremice; right, D2R-Cre
mice). A schemeof this chronic CNO treatment experiment is shownat the top. The arrows indicate injections (blue, rAAV; red, vehicle/CNO). Ipsilateral and contralateralmovementsweremonitored
for 5 minutes. **p% 0.01 from the corresponding vehicle/vehicle group. #p% 0.05, ##p% 0.01 from the corresponding vehicle-CNO group. See details of statistical analyses in Table 2. n.d.,
Nondetectable.
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minergic signaling (mostly via D1R) to induce MSN excitotoxic-
ity (McLaughlin et al., 1998; Tang et al., 2007; Paoletti et al., 2008;
Chen et al., 2013). Moreover, cocaine (Go et al., 2010) andmeth-
amphetamine (Jayanthi et al., 2002) administration, by overstim-
ulating D1R-mediated dopaminergic signaling, induces MSN
death and striatal damage at least in part via JNK, an effect that is
favored by activation of class I mGlu receptors (Jayanthi et al.,
2002; Go et al., 2010). Therefore, our data align well with prior
evidence and strongly support the notion that the JNK cascade
plays a pivotal converging role in mediating the malfunctioning
of striatal circuits that occurs after overactivation of glutamater-
gic and dopaminergic transmission (Chen et al., 2013; Cahill et
al., 2014). Specifically regarding Huntington)s disease, the in-
volvement of JNK in mutant huntingtin-mediated striatal
neurotoxicity is supported by a number of in vitro and in vivo
studies (Apostol et al., 2008; Perrin et al., 2009; Taylor et al.,
2013). Although we are aware that the primary mechanisms un-
derlying the sustained Gq-protein-induced toxicity of MSNs and
the DTA-induced toxicity ofMSNs are conceivably distinct, pilot
experiments conducted in our STHdh cell cultures show that
DTA-induced death also seems to be JNK dependent, as shown
by the preventive effect of SP600125 (authors’ unpublished
observations).
PYK2 was originally characterized as a Ca2!-dependent pro-
tein kinase that can link elevations of cytosolic free Ca2! concen-
tration (Yu et al., 1996) with JNK activation upon different
triggers (Dikic et al., 1996; Tokiwa et al., 1996). PYK2 is highly
responsive to neuronal activity. Upon depolarization, it auto-
phosphorylates on tyrosine residues, clusters on postsynaptic
densities, and exposes an SH2-binding domain that recruits Src
family kinases, thereby activating various signaling pathways
(Girault et al., 1999; Bartos et al., 2010). Therefore, PYK2 may
connect neuronal activity/plasticity with processes such as neu-
ronal survival and neurite outgrowth/retraction (Girault et al.,
1999; Ivankovic-Dikic et al., 2000; Kinoshita et al., 2014). In ad-
dition, PYK2 is activated in the rat hippocampus after brain isch-
emia and kainate-induced convulsions (Tian et al., 2000), which
suggests a role for the kinase in the effects of these insults. There-
fore, our present findings extend this evidence and specifically
show that PYK2 is a novel mediator of Gq/Ca
2!-driven striatal
dysfunction (Fig. 9A).
In conclusion, this work sheds new light onto how metabo-
tropic signals control neuronal integrity and functionality. It also
supports that the sustained DREADDq-evoked modulation of
the direct versus indirect pathwaymay be adopted as a new tool to
understand physiopathological alterations occurring in basal-
ganglia-related diseases such as Huntington’s disease, Parkin-
son’s disease, and L-DOPA-induced dyskinesia. For example,
regarding Huntington’s disease, the impairment of indirect-
pathway circuitry evoked by sustainedGq/JNK signaling seems to
recapitulate the dyskinesia/hyperkinesia, as well as the insomnia/
reduced REM sleep occurring from early stages of the disease,
whereas the impairment of direct-pathway circuitry evoked by
sustained Gq/JNK signaling seems to recapitulate the bradykine-
sia/parkinsonism occurring at later stages of the disease (Fig. 9B;
Walker, 2007; Arnulf et al., 2008). Whether Gq/JNK signaling
affects, not only motor behavior, but also other prominent stria-
tal functions such as cognition andmotivationmay be the subject
of future studies.
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